Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders
August 21 2020 - 9:00AM
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced
that its 2020 Annual Meeting of Stockholders (“Annual Meeting”),
convened on Thursday, August 20, 2020, has been adjourned and will
resume on September 3, 2020 at 10:00 a.m. Pacific Time, to permit
additional time for solicitation of proxies with respect to two of
the proposals described in the company’s notice of meeting and
definitive proxy statement filed with the Securities and Exchange
Commission on July 11, 2020 and any supplements thereto, to approve
an amendment to the company’s restated certificate of incorporation
to increase the number of authorized shares of common stock, and to
approve an amendment to the company’s restated certificate of
incorporation to implement a reverse stock split of the outstanding
common stock, if the board of directors in its discretion
determines to implement a reverse stock split, as described in the
proxy statement. The adjourned meeting will be a completely
"virtual" meeting of stockholders, and stockholders will be able to
listen and participate in the virtual meeting as well as vote and
submit questions during the live webcast of the meeting by visiting
www.virtualshareholdermeeting.com/ADMP2020. To participate in
the virtual meeting, stockholders will need the control number
found on their proxy card or in the instructions that accompanied
their proxy materials. Only stockholders of record on the
record date of June 23, 2020, are entitled to vote. Prior to
adjournment, the director nominees proposed for election in the
company’s definitive proxy statement were elected and the other
proposals described in the notice of meeting and proxy statement,
other than the two proposals described above, were voted on.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a specialty
biopharmaceutical company primarily focused on developing and
commercializing products in various therapeutic areas, including
allergy, respiratory and inflammatory disease. The company’s
SYMJEPI (epinephrine) Injection products are approved by the FDA
for use in the emergency treatment of acute allergic reactions,
including anaphylaxis. Adamis’ naloxone injection product
candidate, ZIMHI, for the treatment of opioid overdose is currently
under FDA review with a target action date of November 15, 2020. In
May 2020, the Company announced a partnership with US WorldMeds for
the commercialization of SYMJEPI and, if approved by the FDA,
ZIMHI. Adamis is developing additional products, including
treatments for acute respiratory diseases, such as COVID-19,
influenza, asthma and COPD. The company’s subsidiary, U.S.
Compounding, Inc., compounds sterile prescription drugs, and
certain nonsterile drugs for human and veterinary use by hospitals,
clinics, and surgery centers throughout most of the United
States.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that are subject to a number of risks and uncertainties. Readers
are cautioned not to place undue reliance on the forward-looking
statements, which speak only as of the date on which they are made
and reflect management’s current estimates, projections,
expectations and beliefs. Certain of these risks,
uncertainties, and other factors are described in greater detail in
Adamis’ filings from time to time with the SEC, including its
annual report on Form 10-K for the year ended December 31,
2019, and our subsequent filings with the SEC, which
Adamis strongly urges you to read and consider, all of which are
available free of charge on the SEC's web site
at http://www.sec.gov. Except to the extent required by
law, any forward-looking statements in this press release speak
only as the date of this press release, and Adamis expressly
disclaims any obligation to update any forward-looking
statements.
Important Information
In connection with the solicitation of proxies, on July 10,
2020, Adamis Pharmaceuticals Corporation filed a definitive proxy
statement with the Securities and Exchange Commission (the “SEC”)
in connection with the Company’s 2020 annual meeting of
stockholders, and filed a Supplement No. 1 to the Proxy Statement
with the SEC on August 7, 2020. The company’s
stockholders are strongly advised to read the definitive proxy
materials, as supplemented, and any other relevant solicitation
materials filed by the company with the SEC before making any
voting or investment decision because these documents contain
important information. The company’s proxy statement
and any other materials filed by the company with the SEC can be
obtained free of charge at the SEC’s web site
at www.sec.gov. The company’s proxy statement, notice of
annual meeting, and annual report to shareholders are available
free of charge on our website at
http://www.adamispharmaceuticals.com. The contents of the
website referenced above are not deemed to be incorporated by
reference into the proxy statement.
Contacts:Mark FlatherSenior
Director, Investor Relations& Corporate CommunicationsAdamis
Pharmaceuticals Corporation(858)
412-7951mflather@adamispharma.com
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Apr 2023 to Apr 2024